From Detection to Decision: Risk-Based Immunogenicity Testing
Immunogenicity describes treatment‑induced B‑ and T‑cell responses to therapeutics and represents a major hurdle for drug development, due to the potential impact on patient safety…
Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective
The radiopharmaceutical industry has traditionally experienced steady but modest growth, primarily driven by its established role in diagnostics and nuclear…
